Board of Directors

Jeffrey Collins

Dr. Collins, a microbiologist with broad experience in virology, immunology and toxicology, is currently an Executive-in-Residence with Pappas Ventures, a life sciences-focused venture capital firm based in RTP.

Prior to joining Pappas Ventures in 2002, Dr. Collins, who has extensive experience in project management and in the administration of basic and clinical research, served in senior management positions at global clinical research organizations (CROs), including PAREXEL International and ClinTrials Research.

Before entering the CRO world, Dr. Collins was at Glaxo, Inc. and Glaxo Wellcome, Inc. for nearly 11 years, where he directed a number of drug development programs in the anti-infectives and oncology areas, resulting in the submission and approval of one NDA and five sNDAs. Dr. Collins also spent 4 years with the National Toxicology Program at NIEHS in a research administration position (Project Officer) and nearly ten years at the Duke University Medical Center (DUMC), where he taught and conducted research in viral and tumor immunology, leaving as an Associate Prof. of Experimental Surgery and of Microbiology.

Dr. Collins received his B.S. in Bacteriology from Cornell University and his Ph.D. in Microbiology and Molecular Genetics from Harvard University. Prior to his faculty appointment at DUMC, Dr. Collins conducted post-doctoral research in Cell Biology at the Imperial Cancer Research Fund Laboratories in Lincoln’s Inn Fields, London, England.